Shares of Endo International PLC (NASDAQ:ENDP) rose 1.1% during trading on Tuesday . The stock traded as high as $17.25 and last traded at $17.06, with a volume of 3,602,319 shares trading hands. The stock had previously closed at $16.88.

ENDP has been the subject of several recent analyst reports. Deutsche Bank AG reissued a “buy” rating and issued a $61.00 price target (down from $65.00) on shares of Endo International PLC in a report on Monday, April 18th. Citigroup Inc. reduced their price target on Endo International PLC from $72.00 to $40.00 and set a “buy” rating for the company in a report on Friday, April 29th. Stifel Nicolaus reduced their price target on Endo International PLC from $90.00 to $75.00 and set a “buy” rating for the company in a report on Friday, May 6th. Guggenheim reissued a “buy” rating and issued a $35.00 price target (down from $65.00) on shares of Endo International PLC in a report on Saturday, May 7th. Finally, JMP Securities reissued a “buy” rating and issued a $52.00 price target (down from $56.00) on shares of Endo International PLC in a report on Sunday, May 8th. One analyst has rated the stock with a sell rating, twelve have given a hold rating and ten have issued a buy rating to the company. Endo International PLC presently has an average rating of “Hold” and an average price target of $39.16.

The stock’s market capitalization is $4.05 billion. The stock’s 50 day moving average price is $16.88 and its 200-day moving average price is $29.38.

Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings data on Thursday, May 5th. The company reported $1.08 EPS for the quarter, beating analysts’ consensus estimates of $1.04 by $0.04. During the same quarter last year, the company posted $1.17 EPS. The company had revenue of $963.54 million for the quarter, compared to analyst estimates of $960.96 million. Endo International PLC’s revenue was up 34.9% on a year-over-year basis. On average, analysts forecast that Endo International PLC will post $4.55 EPS for the current year.

In related news, Director Arthur J. Higgins acquired 11,000 shares of the business’s stock in a transaction dated Tuesday, May 10th. The stock was bought at an average price of $15.42 per share, for a total transaction of $169,620.00. Following the transaction, the director now owns 45,623 shares of the company’s stock, valued at $703,506.66. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Arthur J. Higgins acquired 5,000 shares of the business’s stock in a transaction dated Wednesday, May 11th. The shares were bought at an average price of $13.80 per share, with a total value of $69,000.00. Following the transaction, the director now directly owns 50,623 shares in the company, valued at approximately $698,597.40. The disclosure for this purchase can be found here.

Several large investors recently made changes to their positions in ENDP. Advantus Capital Management Inc increased its stake in shares of Endo International PLC by 2.4% in the fourth quarter. Advantus Capital Management Inc now owns 19,971 shares of the company’s stock worth $1,223,000 after buying an additional 476 shares during the period. BNP Paribas Arbitrage SA raised its stake in Endo International PLC by 4.7% in the fourth quarter. BNP Paribas Arbitrage SA now owns 273,393 shares of the company’s stock worth $16,737,000 after buying an additional 12,234 shares during the last quarter. RS Investment Management Co. LLC raised its stake in Endo International PLC by 29.5% in the fourth quarter. RS Investment Management Co. LLC now owns 543,593 shares of the company’s stock worth $33,279,000 after buying an additional 123,692 shares during the last quarter. Finally, Cibc World Markets Corp acquired a new stake in Endo International PLC during the fourth quarter worth about $47,081,000.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.